FPT-SOFTWARE/SCSK-EU
19.4.2022 05:02:12 CEST | Business Wire | Press release
Vietnam’s leading Digital Transformation services provider FPT Software has recently unveiled its partnership with SCSK Europe, a subsidiary of the Japan-based system integrator SCSK Corporation. The collaboration affirms FPT Software’s robotic process automation (RPA) expertise and further expands its foothold in the European market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220418005262/en/
Applying “Fast Automation” framework, FPT Software has successfully helped SCSK Europe streamline six internal processes by deploying its award-winning RPA platform akaBot in four weeks. The offshore team then provided a comprehensive understanding of RPA’s benefits and armed SCSK employees with the necessary skills and mentality for the upcoming changes with the emergence of digital transformation. Following their internal success, SCSK Europe introduced FPT Software’s akaBot to their clients in the Chemical and Agriculture industries to help replace 100 percent human effort in their data extraction and loan credits approval processes.
"RPA is a powerful tool to resolve the bottleneck in business processes, delivering a much streamlined and efficient workflow. We believe that we can always extend the automation horizons even more by integrating RPA robots with other intelligent technologies,” said Masatoshi Chiba – General Manager, SCSK EU.
“With that expectation in mind, we decided to partner with akaBot, one of the leading vendors in developing hyper-automation solutions from FPT. Since 2018, we have established MOU for the comprehensive partnership to seek to supply a wider range of services and solutions and to expand our operations in the global through this partnership with FPT," Masatoshi Chiba further shared.
According to FPT Software Chief Operating Officer Tran Dang Hoa, the collaboration "paved the way for FPT Software’s expansion in robotic automation and digital transformation in the EU and on a global scale."
"Like SCSK, more and more firms worldwide are adopting RPA and hyper-automation to enhance operations," Tran Dang Hoa said. "As a global top 30 RPA solution provider, we aspire to accompany businesses to overcome pressing challenges, boost their productivity and save costs," he added.
FPT Software and SCSK’s partnership dates back to 2018 when the two cooperated in supporting the overseas expansion of Japanese companies, especially in financial and automotive systems development. Both sides joined forces in providing IT Services and business development through the Asia Pacific operations of major SCSK’s shareholder – Sumitomo Corporation.
First entering the European market in 2008, FPT Software has established seven offices and development centers, and is determined to penetrate further with digital transformation as the key driving force. The global IT firm targeted this strategic area as its first port for capital commitment in the value of 100 million dollars in the upcoming years, with the UK and Germany as two major geographies.
About FPT Software
FPT Software is a global technology and IT services provider headquartered in Vietnam, with USD 632.5 million in revenue and 22,500 employees in 26 countries. As a pioneer in digital transformation, the company delivers world-class services in Smart factories, Digital platforms, RPA, AI, IoT, Cloud, AR/VR, BPO, and more. It has served 700+ customers worldwide, a hundred of which are Fortune Global 500 companies in the industries of Automotive, Banking and Finance, Logistics & Transportation, Utilities, and more. For further information, please visit http://www.fpt-software.com .
About SCSK EU
SCSK Europe Ltd. was established in London in 1990 as a fully-owned subsidiary of SCSK Corporation, one of Japan's leading IT service companies with more than 14,000 employees. We are One Stop IT Service Provider and a proven strategic business partner to Japanese-related corporations operating in EMEA/CIS providing various IT Solutions including RPA. For further information, please visit SCSK Europe Ltd.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005262/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release
Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d
Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release
New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel
HyperLight Announces $80 Million Series C to Accelerate TFLN Deployment for AI Infrastructure18.6.2026 17:30:00 CEST | Press release
HyperLight Corporation (“HyperLight”), a leader in thin-film lithium niobate (TFLN) photonics, today announced the closing of an $80 million Series C financing round led by MediaTek. The round includes participation from UMC Capital, Jabil, Foxconn, EDBI (arm of SG Growth Capital, the investment platform of the Singapore Economic Development Board and Enterprise Singapore), CDIB-TEN Capital, and Qatar Investment Authority (QIA), as well as strategic investors from leading silicon IC and networking companies. Existing investors Summit Partners, The Engine, Foothill Ventures, and Xora Innovation continue to actively support the company’s growth. The financing brings together companies across the AI infrastructure value chain — including silicon ICs, foundry manufacturing, electronics manufacturing services, networking, and global infrastructure investment — reflecting broad ecosystem support for scaling TFLN photonics into production. “This financing is about more than capital — it is ab
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom